Cosentyx is a brand name for secukinumab, a monoclonal antibody used in the treatment of several chronic autoimmune conditions. It works by targeting and inhibiting interleukin-17A (IL-17A), a protein involved in inflammation and immune responses.
Product Highlights
Cosentyx is a biologic medication that specifically targets IL-17A to reduce inflammation.
Administered via subcutaneous injections, typically in the abdomen or thigh.
Designed to target specific inflammatory pathways associated with autoimmune diseases.
Key Ingredient
Secukinumab
Key Benefits
Effectively decreases inflammation by targeting IL-17A, which helps alleviate symptoms associated with autoimmune conditions.
Provides significant improvement in skin symptoms for plaque psoriasis, joint symptoms for psoriatic arthritis, and spinal symptoms for ankylosing spondylitis.
Administered via subcutaneous injection, which can be done at home after initial training by a healthcare provider.
Often results in sustained symptom relief with regular dosing.
Direction of Use
The initial dosing schedule usually includes more frequent injections, followed by maintenance doses. The exact regimen is determined based on the condition being treated.
Cosentyx is administered as a subcutaneous injection, typically in the abdomen or thigh. Training from a healthcare provider is recommended for proper self-administration.
Regular follow-up with a healthcare provider is essential to monitor efficacy and manage any potential side effects.
Recommended infusion bag sizes for the dilution and preparation of COSENTYX for intravenous use, based on body weight and dosage:
Body weight at time of dosing
For the loading dose (6 mg/kg) recommended infusion bag
For maintenance dose (1.75 mg/kg) recommended infusion bag
Greater than 52 kg
100 mL
100 mL
Less than or equal to 52 kg
100 mL
50 mL*
*If a 50 mL infusion bag is not available, use a 100 mL infusion bag instead. Withdraw and discard 50 mL of saline using aseptic technique, then proceed with the preparation and administration steps as directed.
Safety Concerns
Common side effects may include upper respiratory infections, headaches, fatigue, and reactions at the injection site. Serious side effects can include an increased risk of infections and potential impact on immune system function.
Patients should be monitored for signs of infections, as Cosentyx can suppress immune response.
Rare but possible; patients should seek medical attention if they experience severe allergic reactions.
Avoid Cosentyx (Secukinumab) If
Avoid use in patients with active infections or a history of recurrent infections.
Do not use in individuals with a known hypersensitivity to secukinumab or any of the components in the formulation.
Avoid concurrent use of live vaccines due to potential interactions with the immune system.
Use with caution in individuals with a history of certain chronic infections or conditions that might be exacerbated by immune system modulation.
